0.05
0.00%
Close of 9 Nov 2026, in AUD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Arovella Therapeutics
Its shares trade on ASX under the ticker ALA.AX. It has been listed since 24 January 2002. In the fiscal year to 30 June 2025, it reported revenue of A$525,500 and a net loss of A$7.5m. At that date it held total assets of A$21.6m and shareholders' equity of A$20.1m.
Arovella Therapeutics Ltd. develops pharmaceuticals and distributes medical devices and consumables. The firm is focused on developing therapies to treat human disease. The firm focuses two focus areas are oncology and conditions that impact the central nervous system. The Company’s technology includes iNKT Cell Therapy, DKK1-CAR-iNKT, AR19-iNKT + CF33-CD19, Anagrelide and ZolpiMist. The Company’s invariant natural killer T (iNKT) cell therapy pipeline through the license to the DKK1 monoclonal antibody (mAb). The company develops the DKK1 mAb as a chimeric antigen receptor to use in combination with its iNKT cell therapy platform. The firm is developing its invariant natural killer T (iNKT) cell therapy platform from Imperial College London to treat blood cancers and solid tumors. Anagrelide is for the treatment of metastatic disease granted in the United States, Europe, Japan and Australia. ZolpiMist is an oral spray of zolpidem tartrate to treat short- term insomnia.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 24 Jan 2002
- Website
- arovella.com ↗
Leadership
Pay as last reported
- Dr. Thomas DuthyNon-Executive Chairman of the Board
- Mr. Michael BakerChief Executive Officer, Managing Director, Director, since 2020
- Mr. Tim LuscombeChief Financial Officer, Company Secretary
- Dr. Nicole van Der WeerdenChief Operating Officer
- Dr. Elizabeth StonerNon-Executive Director
- Dr. Debora BartonNon-Executive Independent Director
- Mr. Gary PhillipsIndependent Non-Executive Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Arovella Therapeutics Ltd. focuses on oncology and central nervous system therapies with iNKT Cell Therapy platform.
- Anagrelide is approved in the United States, Europe, Japan, and Australia for metastatic disease treatment.
- ZolpiMist provides an oral spray solution for short-term insomnia using zolpidem tartrate.
Weaknesses
- The company's pipeline relies on a single technology platform from Imperial College London.
- Arovella Therapeutics Ltd. has no product approvals beyond Anagrelide and ZolpiMist.
- The firm's focus on blood cancers and solid tumors limits broader market reach.
Opportunities
- Expanding DKK1-CAR-iNKT therapy to new markets could increase revenue streams.
- Collaborating with Imperial College London may enhance iNKT cell therapy development.
- Leveraging Anagrelide's global approvals for additional indications could grow market share.
Threats
- Competition from established pharmaceutical companies in oncology and CNS markets.
- Regulatory challenges for new therapies like DKK1-CAR-iNKT in multiple countries.
- Potential delays in clinical trials for AR19-iNKT + CF33-CD19 therapy platform.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.